for disseminated MAC infection is unclear. We compared azithromycin plus ethambutol with clarithromycin plus ethambutol in the treatment of disseminated MAC infection in HIV type 1 -infected patients, examining the frequency of bacteremia clearance, time to clearance, and study drug tolerance after 16 weeks of therapy. Fifty-nine patients for whom blood cultures were positive for MAC were enrolled in the study from 10 university-affiliated Veterans Affairs Medical Centers. Thirtyseven patients were evaluable for determination of quantitative bacteremia and clinical outcomes. Clearance of bacteremia was seen at the final visit in 37.5% of azithromycin-treated patients and in 85.7% of clarithromycin-treated patients (P Å .007). The estimated median time to clearance of bacteremia was also significantly different between the two treatment arms: 4.38 weeks for clarithromycin recipients vs. ú16 weeks for azithromycin recipients (P Å .0018). Only one isolate developed macrolide resistance during therapy. Abatement of symptoms, other laboratory-evident abnormalities, and adverse effects were similar in the two groups. At the doses used in this study, clarithromycin/ethambutol produced a more rapid resolution of bacteremia than did azithromycin/ethambutol, and clarithromycin/ethambutol was more effective at sterilization of blood cultures after 16 weeks of therapy. In vitro studies and recent human trials suggest that macroby sustained bacteremia, with intermittent fever, night sweats, lide-based combination antimycobacterial therapy should be abdominal pain, and weight loss [2]. Disseminated MAC infecused to treat disseminated MAC infection [4 -6]. Yet, the optition has been shown to be an independent predictor of mortality mal therapeutic regimen for treatment of disseminated MAC [3] . Treating disseminated infection can lead to both an iminfection is unknown [4] . Since macrolide monotherapy leads provement in the clinical condition and a decrease in the bacteto the occurrence of drug resistance and resultant clinical failure [4] , recent studies have evaluated several different macrolidebased combination regimens [4 -7]. Ethambutol and clofazimine have the best tolerance patterns of nonmacrolide drugs
Disseminated Mycobacterium avium complex (MAC) infecrial load and has been shown to prolong survival [4] . Previous tion remains the most common opportunistic bacterial infection studies have demonstrated that quantitative changes in the level in adults infected with HIV type 1 in the United States, despite of mycobacteremia are a reliable indicator of therapeutic rerecent advances in antiretroviral therapy and chemoprophylaxis sponse [4 -6] . for MAC infection [1] . Infection is characterized clinically
In vitro studies and recent human trials suggest that macroby sustained bacteremia, with intermittent fever, night sweats, lide-based combination antimycobacterial therapy should be abdominal pain, and weight loss [2] . Disseminated MAC infecused to treat disseminated MAC infection [4 -6] . Yet, the optition has been shown to be an independent predictor of mortality mal therapeutic regimen for treatment of disseminated MAC [3] . Treating disseminated infection can lead to both an iminfection is unknown [4] . Since macrolide monotherapy leads provement in the clinical condition and a decrease in the bacteto the occurrence of drug resistance and resultant clinical failure [4] , recent studies have evaluated several different macrolidebased combination regimens [4 -7] . Ethambutol and clofazimine have the best tolerance patterns of nonmacrolide drugs Received 8 January 1998; revised 15 July 1998. that have predictable in vitro activity against MAC infection
This work was presented in part at the 34th annual meeting of the Infectious [4] , although clofazimine when given with clarithromycin neiDiseases Society of America held in New Orleans on 18 -20 September 1996. ther prevents emergence of resistance to clarithromycin nor therapy [6 -8] .
MAC infection. Therefore, we performed a randomized treatmycobacterial cultures in this manner does not affect viability or quantitative results [12] . Susceptibility testing of isolates to ment trial comparing the efficacy and tolerability of azithromycin plus ethambutol with those of clarithromycin plus ethclarithromycin and azithromycin was performed by methods previously described by Heifets [13] . ambutol as treatment of disseminated MAC infection in HIVseropositive patients. Our study was limited to 16 weeks and employed a quantitative microbiological primary outcome mea-
Assessment of Efficacy
sure. Signs, symptoms, and laboratory-evident abnormalities of disseminated MAC infection; study drug tolerance; and antiInvestigators were blinded to results of quantitative blood biotic resistance were also assessed.
cultures and susceptibility testing but not to treatment group. The primary study outcome was the proportion of patients with clearance of bacteremia at the final 16-week study visit. A Methods subgroup analysis by level of baseline bacteremia (õ10 1 and §10 1 cfu/mL) of this primary end point was a planned part of
Study Patients
the study design. Secondary outcomes included the rate of Patients were eligible for enrollment in the study if they decrease in bacterial load in quantitative blood cultures, the were HIV-1-seropositive, had a blood culture positive for MAC duration in weeks to the first negative blood culture, clinical within 2 weeks, and were at least 18 years old. Patients were response, and laboratory findings. Patients were considered excluded from the study if they had received azithromycin, evaluable with regard to bacteriologic and clinical responses clarithromycin, or ethambutol within 4 weeks before enrollto therapy if they had a positive quantitative culture at baseline, ment, had hypersensitivity to any of the study agents, had other had at least one subsequent quantitative culture performed concurrent mycobacterial disease such as tuberculosis, had a while receiving therapy, and received study drugs for a minilife expectancy estimated to be õ16 weeks, or were unable to mum of 4 weeks. take or comply with the oral study regimen. Patients were enrolled at 10 university-affiliated Veterans Affairs Medical Centers and at affiliated institutions. The study was approved
Statistical Analyses
by the ethics committees at each center, and each participant Analyses were done to compare baseline characteristics begave informed consent.
tween groups and to compare treatment outcomes. Differences in categorical variables were assessed with the continuitycorrected x 2 test. Normally distributed continuous variables
Study Drug Therapy
within groups were compared with the paired t test, and skewed Patients were randomly assigned to one of two treatment variables were compared with the Wilcoxon rank-sum test. The arms by using an automated phone-in registration process: median time to negative blood cultures was estimated by using 600 mg of azithromycin once daily plus ethambutol or 500 mg the product limit method, with differences assessed by the of clarithromycin twice daily plus ethambutol. The dose of logrank test. An interim analysis of the primary outcome was ethambutol was either 800 mg daily if the patient's weight was conducted after approximately one-half the projected sample õ60 kg or 1,200 mg daily if the patient's weight was §60 kg. size of 108 patients had been randomized; the committee performing the interim analysis was blinded to specific study regimen assignments. All adverse reactions were reviewed by a
Clinical and Microbiological Evaluation
data management and safety board whose members were Clinical symptoms, Karnofsky scores, adherence to the study blinded to the study arm assignment. drug regimen, and adverse events were recorded at 2 weeks, 4 weeks, and then every 4 weeks thereafter for the 16-week Results study duration. Clinical symptoms that were evaluated included fever, night sweats, and abdominal pain; laboratory parameters
Study Patients
included levels of hemoglobin, alkaline phosphatase, and alanine or aspartate aminotransferase. Quantitative blood cultures Between November 1991 and October 1994, 59 patients were enrolled in the study: 35 in the clarithromycin arm and for determination of mycobacteremia were performed in duplicate at baseline before study therapy was initiated and then 24 in the azithromycin arm. The study was stopped after an interim analysis demonstrated a significant difference every 4 weeks for the 16-week study period. Specimens were sent to the Mycobacteriology Clinical Reference Laboratory at (P Å .028) between study arms in the proportion of patients for whom cultures were negative at 16 weeks. A skew in the the National Jewish Medical and Research Center for Immunology and Respiratory Medicine in Denver and were assessed by randomization between study arms resulted from the termination of the study earlier than originally projected. Of 59 patients previously reported methods [12] . Specimens were shipped at ambient temperature by overnight mail to Denver; shipping of enrolled in the study, 37 (21 in the clarithromycin arm and 16 weeks included the following: investigator's concern with possible clinical failure (occurring for two azithromycin recipients and one clarithromycin recipient); patient request to withdraw in the azithromycin arm) were evaluable for microbiological from the study on three occasions; two episodes of increasing and clinical outcomes. The remaining 22 patients either had inadequate documentation of microbiological response or did not receive adequate therapy to evaluate efficacy. Twelve pa- performed on all baseline and final study visit isolates from those patients whose cultures remained positive at the time of study termination. Only one 16-week isolate from a patient in disability; and death at 8 weeks of therapy in two patients.
the clarithromycin arm was definitely resistant to the study Adherence to the study drug regimen, as assessed by pill macrolides (MIC of clarithromycin, ú32 mg/mL; MIC of counts, was similar for the two arms and improved after the azithromycin, ú256 mg/mL). The baseline isolate from this 2-week study visit.
patient was susceptible to both macrolides (MIC of clarithromycin, £2.0 mg/mL; MIC of azithromycin, £16 mg/mL). Although a progressive decline in the quantitative level of bacter-
Microbiological Response
emia was demonstrated at each study visit for this patient, he was the only patient in the clarithromycin arm whose culture MAC bacteremia was cleared in 65% of the 37 evaluable patients at the final study visit. The proportion of patients with clearance of bacteremia at the final study visit was 37.5% in the azithromycin arm and 85.7% in the clarithromycin arm (P Å .007). The proportion of patients with negative blood cultures was significantly different at weeks 8 (P Å .006) and 16 (P Å .028) but not at week 12 (P Å .29; figure 1 ). The estimated median time to clearance of bacteremia (figure 2) was also significantly different (P Å .0018, by the logrank test) for the two treatment groups: 4.38 weeks for the clarithromycin arm vs. ú16 weeks for the azithromycin arm. The median level of bacteremia for the two treatment groups did not differ significantly at any study visit (table 2). At 4 weeks of therapy, the geometric mean reduction in colony counts from baseline was 1.2 and 1.4 logs for the azithromycin and clarithromycin arms, respectively. At 12 weeks, the geometric mean reduction was 1.2 and 1.6 logs, respectively.
An intent-to-treat analysis of the 59 enrolled patients demonstrated a significant difference (P Å .011) in the proportion of There were eight deaths during study drug therapy, four in each of the treatment arms. Six deaths occurred within 3 weeks of study enrollment. MAC infection was not listed as the primary cause of death for any patient. Six deaths were classified remained positive at the 16-week study visit (baseline, 554 cfu/mL; week 16, 7 cfu/mL).
as not related to study therapy. Two deaths in the azithromycin arm were due to sudden cardiac arrest without a certain etiolThree patients in the azithromycin arm had isolates with an MIC equal to 64 mg/mL and were considered susceptible by ogy, and it was not possible to determine a relationship to the study drug. Both patients had other ongoing diseases that may the central reference laboratory [13] . Two of these three isolates were recovered from baseline cultures for patients whose final have contributed to sudden death: cytomegalovirus retinitis in one case and recently diagnosed Pneumocystis carinii pneumostudy visit isolates were definitely susceptible to azithromycin (MIC, õ16 mg/mL); a progressive decline in the quantitative nia in one case. Alanine or aspartate aminotransferase levels were measured in all patients at each study visit to assess level of bacteremia during therapy was demonstrated for both patients. The third isolate for which the MIC of azithromycin possible study drug hepatotoxicity. Only two patients in each treatment arm had alanine or aspartate aminotransferase levels was 64 mg/mL was from a patient at the final study visit who had a baseline isolate for which the MIC was õ16 mg/mL; a that increased §20% between the baseline and the final study visit; no value was greater than three times the upper limit of progressive decline in the quantitative level of mycobacteremia during therapy also was demonstrated for this patient. All three normal at any study visit. isolates for which MICs of azithromycin were 64 mg/mL were susceptible to clarithromycin (MIC, £2 mg/mL).
Discussion
Our study confirmed that macrolide-based two-drug therapy
Clinical Response
results in significant reduction in the level of mycobacteremia in HIV type 1 -seropositive patients with disseminated MAC At the final study visit, the frequency of patients with symptoms of fever and night sweats decreased from that at baseline infection. As in prior studies, the microbiological response was accompanied by a decrease in constitutional symptoms of MAC in both arms (table 3). The effect on abdominal pain was less marked. Little change in laboratory-evident abnormalities, disease [4] . Although the primary end point of our study was clearance of mycobacteremia at 16 weeks and thus our study weight, or Karnofsky score was observed over the 16-week study duration in either arm. At study termination, the fredid not extend to a longer follow-up, previous trials have correlated short-term improvement as evidenced by microbiological quency with which the hemoglobin level was õ8 g/dL had increased over that at baseline in both arms. No patient in and clinical responses with increased survival [4 -7, 14 -18] .
/ 9c5b$$no42 10-14-98 15:53:24 cida UC: CID To our knowledge, this is the first randomized trial to directly trial [6] , 23 (82%) of 28 patients randomized to clarithromycin, clofazimine, and ethambutol had sterile blood cultures after 16 compare azithromycin with clarithromycin as therapy for disseminated MAC disease.
weeks of therapy. At 12 weeks, we noted that the geometric mean reduction in colony counts was 1.2 and 1.6 logs for At the macrolide doses employed in this study, the bacteriologic response in the azithromycin/ethambutol arm was delayed the azithromycin and clarithromycin arms, respectively. These results are similar to those reported for 500 mg of clarithroin comparison with that in the clarithromycin/ethambutol arm, and the clarithromycin/ethambutol arm was more effective at mycin twice daily [14] and 600 mg of azithromycin once daily [20] . Differences between studies in the level of baseline bacsterilization of blood cultures after 16 weeks of therapy. The two treatment arms were comparable in terms of clinical and teremia influence the size of the treatment effect seen and preclude any direct comparison of our findings with historical other laboratory findings over the 16-week treatment duration. Drug tolerance also appeared equivalent in the two study drug controls.
Results of in vitro susceptibility testing in our study demonarms. Acquisition of macrolide resistance in vitro after 16 weeks of combined treatment with a macrolide and ethambutol strated minimal macrolide resistance in either treatment arm after 16 weeks of therapy. Isolates from only one of the 37 was infrequent, thus confirming the finding of a protective effect of adding ethambutol that was recently reported in a evaluable patients showed in vitro macrolide resistance. This observation supports the recently reported findings of Dubé et California Collaborative Treatment Group trial [6] . Our observed time to clearance of bacteremia in the clarithromycin/ al. [6] who noted that the addition of ethambutol to a macrolide reduced the frequency of acquisition of drug resistance; in that ethambutol arm was shorter than that reported in prior trials that evaluated three-and four-drug treatment regimens lacking trial, relapse occurred only in patients whose isolates developed clarithromycin resistance, which was seen in õ10% of isolates a macrolide component [4] . Our observations are consistent with other recently reported studies employing macrolide-based from 25 patients after 16 weeks of therapy. Dubé et al. reported that the time to development of resistance that was associated therapies [5 -8] .
The optimal dose of either clarithromycin or azithromycin with the addition of ethambutol to clarithromycin plus clofazimine was significantly longer than the time to development of for treating MAC infection is unknown. A dose-ranging monotherapy trial with clarithromycin demonstrated more rapid resistance that was associated with two-drug therapy without ethambutol. These results are consistent with in vitro, ex vivo, clearance of bacteremia with higher doses [14] . We evaluated a dosage of clarithromycin of 500 mg twice daily on the basis and animal studies that demonstrated augmentation of clarithromycin's antimycobacterial activity by the addition of ethambuof studies reported by Chaisson and colleagues [14] who compared three dosages of clarithromycin monotherapy (500 mg, tol [6, 21 -24] . In our trial, the addition of ethambutol did not appear to add 1,000 mg, and 2,000 mg twice daily) and found that the lowest mortality rate during the first 12 weeks was associated with to the toxicity that has been previously reported for macrolide therapy. The 8.5% (five of 59) frequency of treatment-terminatthe dosage of 500 mg twice daily. A second randomized trial, conducted by the Community Program for Clinical Research ing toxicities that we observed was consistent with the frequency of 7% -10% that was reported by Dubé et al. [6] for in AIDS, was modified after an interval analysis showed that survival was better with 500 mg of clarithromycin twice daily clarithromycin/ethambutol/clofazimine; the duration of their study was approximately twice that of our trial. Therapy in our than with 1,000 mg twice daily [19] . Last, in a recent study where patients were randomized to a dosage of clarithromycin study was withheld because of possible drug-related adverse effects on only 1.1% of 3,480 aggregate study days, and the of 1,000 mg twice daily, 54% of patients required dosage reduction because of gastrointestinal side effects [6] . The dose of overall rate of adherence as assessed by pill counts was ú80% for both macrolides. azithromycin chosen for this trial was based on more limited data [20] , but it was our opinion that the daily dose of 600 mg
The major limitation of our trial was the relatively small sample size. We observed a progressive decline in the rate of was comparable with the twice daily dose of 500 mg employed in the clarithromycin arm.
enrollment as the use of chemoprophylaxis for MAC infection became widespread. A decision to stop our study after 59 paThe microbiological response that we observed in both treatment groups was comparable with that reported previously for tients were randomized rather than proceed to the projected sample size of 108 patients occurred only after an analysis of clarithromycin and azithromycin monotherapies [14, 20] . At the 8-week study visit, we noted clearance of bacteremia in the range in frequencies of bacteremia clearance that could possibly be observed if the trial was continued. The risk ratio 21% and 75% of patients randomized to the azithromycin and clarithromycin arms, respectively. Chaisson and colleagues for a reduction in the frequency of clearance of bacteremia at 16 weeks for those patients in the clarithromycin arm, as com- [14] reported that 41% of patients had negative blood cultures after 8 weeks of clarithromycin monotherapy, and Berry et al. pared with those in the azithromycin arm, was 2.04 (95% CI, 1.1 to 4.0). Although there is imprecision regarding the possi- [20] reported that 54% of patients had negative blood cultures after 6 weeks of treatment with 600 mg of azithromycin once bility of a difference between treatment arms, the likelihood of a reversal in the trend that favored clarithromycin was daily. In the recent California Collaborative Treatment Group / 9c5b$$no42
10-14-98 15:53:24 cida UC: CID
